A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C.
about
Antioxidant supplements for liver diseasesPrevention of hepatocellular carcinoma: Focusing on antioxidant therapyNonalcoholic fatty liver disease: new treatmentsHepatitis C Virus Triggers Mitochondrial Permeability Transition with Production of Reactive Oxygen Species, Leading to DNA Damage and STAT3 Activationc-Myb modulates transcription of the alpha-smooth muscle actin gene in activated hepatic stellate cellsVitamins in the treatment of chronic viral hepatitis.Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas.Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trialCoinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami.The use of selected nutrition supplements and complementary and alternative medicine in liver disease.Current best treatment for non-alcoholic fatty liver disease.Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches.Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stressAntioxidants as therapeutic agents for liver disease.Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosisTargeted treatments for cirrhosis.Hepatitis C virus infection and nonalcoholic steatohepatitisAntifibrotic agents for liver disease.Emerging therapies for liver fibrosis.Fucoidan partly prevents CCl4-induced liver fibrosis.Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in ratsMatrix metalloproteinase gene delivery for liver fibrosisGene modulation for treating liver fibrosisBioconjugation of oligonucleotides for treating liver fibrosis.VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.Current and future anti-fibrotic therapies for chronic liver disease.Potential role of lycopene in the treatment of hepatitis C and prevention of hepatocellular carcinoma.Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapiesReview article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.An insight into the diagnosis and pathogenesis of hepatitis C virus infection.Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C.Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.Attenuation of N-nitrosodiethylamine-induced liver fibrosis by high-molecular-weight fucoidan derived from Cladosiphon okamuranus.Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1.Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C.Reversal of liver fibrosis.What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C?N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity.Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C.
P2860
Q24235796-09FFC937-8DF8-4DE8-ACA1-D5710929B983Q26853520-815E0D56-3451-4F93-BB05-9D3E985FD0EDQ27021161-71FF9367-30FA-41A8-B1E1-C2721FD976B8Q27473285-884F91CE-6B3D-4AEB-9704-FFE3F6A2DFDFQ28568750-2A6B24BD-5A10-470D-89CF-E41EAFC702B3Q33800048-58340531-153B-4B80-B997-A6862D0E2BE1Q33867088-4659F29E-78DA-4A10-94B7-E99CC3B148F1Q34225721-BF6BCDCA-2CCD-4166-86E1-1699477D978AQ34279897-ACAB65B7-06DA-4A12-8363-0F02A88D3E05Q34554574-10376ADB-38DA-437E-8BAA-7286101BAB9EQ35124679-2C5BF9CF-8A6D-4B8F-A35C-38805311F683Q35209239-65C77714-5835-41E8-BB1B-CABA8B1A9C0DQ35259669-998CFA89-6AB9-45AB-A873-6C5CA0DB33CDQ35585469-D4E7F15F-D7F5-43BA-A749-13303DA9A9A6Q35621270-C1BABAE9-E986-4680-AF0C-B7041A35A3CDQ35911123-5D4A7EAA-173D-4095-BD5C-709ED7CEBA34Q36179898-1A0B5CE9-BDF4-417B-9990-AB6B876F1638Q36376477-D61862F3-3AE6-49E4-B9E0-B06EBECD999CQ36478124-449BFB3D-A24D-4437-82C7-9889DAB3491FQ36482392-175A0C11-757A-4D03-97B0-4CEBC9CA081DQ36541169-392F4DA8-FDA5-4790-99FD-68DD026F1328Q36852793-A7C63A09-CB21-4D65-A533-6A7255B79613Q36921638-2156D0B8-9F0F-49B2-B48B-5C92FE8A071EQ37043515-815B0974-0D0D-4420-B063-CA423FFD0F6CQ37130717-32BEB555-D0E8-4870-8DE0-232B1736AFEDQ37317654-C38A1361-C39D-47E6-8D0A-2C885A1F66B7Q37324402-045E6CB6-5017-43A9-A682-45E03857E3EDQ37345868-7AA7B641-8CF7-4A6C-B0F4-4D1C86BFF3F7Q38073028-64704D96-213A-4021-BA9C-D5723754F2C7Q38166445-A6F491B1-91F9-4C4E-AA40-C11C70146D28Q38168827-3CB5A356-F135-4701-90FC-145B329E676BQ40211269-E109A327-80EE-4D73-9037-1594DBDD400FQ42591676-8ABD0F5D-5D28-487F-86F8-8421BC6E87E2Q42873630-28406F5B-C6DA-48BA-872E-F142FA2F459DQ42994110-EFF8F373-EC02-48EE-9A90-8D2D74505547Q42994111-15FE091F-B23B-4294-ABEE-C5F980B5D7AAQ43104809-D3AE10BF-E5BD-4B6C-9AB6-1F59099F3C84Q43505689-917E9A89-2CDE-4B0E-885A-F7959DC672D1Q43710107-7637450F-56BA-49F4-B557-5308E2D24DFFQ43871989-7A6D7B15-20CA-456E-83CA-A1DB47FB5378
P2860
A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
A pilot study of the effects o ...... vation in chronic hepatitis C.
@en
A pilot study of the effects o ...... vation in chronic hepatitis C.
@nl
type
label
A pilot study of the effects o ...... vation in chronic hepatitis C.
@en
A pilot study of the effects o ...... vation in chronic hepatitis C.
@nl
prefLabel
A pilot study of the effects o ...... vation in chronic hepatitis C.
@en
A pilot study of the effects o ...... vation in chronic hepatitis C.
@nl
P2093
P1433
P1476
A pilot study of the effects o ...... vation in chronic hepatitis C.
@en
P2093
Chojkier M
Venkataramani A
P304
P356
10.1053/GAST.1997.V113.PM9322499
P407
P577
1997-10-01T00:00:00Z